kw.\*:("IMAO A")
Results 1 to 25 of 252
Selection :
Aurorix : Generic name : MoclobemideSNAPE, M; MALLARKEY, G.Current therapeutics. 1996, Vol 37, Num 5, pp 87-88, issn 0311-905XArticle
Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemideMAYERSOHN, M; GUENTERT, T. W.Clinical pharmacokinetics. 1995, Vol 29, Num 5, pp 292-332, issn 0312-5963Article
Preclinical profile of befloxatone, a new reversible MAO-A inhibitorCURET, O; DAMOISEAU-OVENS, G; SAUVAGE, C et al.Journal of affective disorders. 1998, Vol 51, Num 3, pp 287-303, issn 0165-0327Article
A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depressionDE WILDE, J. E; GEERTS, S; VAN DORPE, J et al.Acta psychiatrica Scandinavica. 1996, Vol 94, Num 6, pp 404-410, issn 0001-690XArticle
Regional and molecular separation of the four bioactivities of 'tribulin'HUCKLEBRIDGE, F; DOYLE, A; PANG, F.-Y et al.Neuroscience letters. 1998, Vol 240, Num 1, pp 29-32, issn 0304-3940Article
Dextrométhorphane : Vickx toux sèche : capsules de suspension buvable = Dextromethorphan : Vicks toux seche® : capsules of drinkable suspensionLa Revue Prescrire. 1996, Vol 16, Num 166, issn 0247-7750, p. 690Article
Placebo-controlled trial of moclobemide in social phobiaSCHNEIER, F. R; GOETZ, D; CAMPEAS, R et al.British journal of psychiatry (Print). 1998, Vol 172, Num JAN, pp 70-77, issn 0007-1250Article
Hypertension artérielle sous moclobémide (moclamine°) = Moclobemide and hypertensionLa Revue Prescrire. 1996, Vol 16, Num 163, issn 0247-7750, p. 459Article
Influence of age, frailty and liver function on the pharmacokinetics of brofaromineZEEH, J; FUCHS, L; BERGMANN, W et al.European journal of clinical pharmacology. 1996, Vol 49, Num 5, pp 387-391, issn 0031-6970Article
RS-8359, a putative candidate for the treatment of depressionMONTGOMERY, Stuart A.International clinical psychopharmacology. 1997, Vol 12, issn 0268-1315, 38 p., SUP5Serial Issue
Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide. A case reportVAIVA, Guillaume; DE CHOULY DE LENCLAVE, Marie Bérengère; BAILLY, Daniel et al.Progress in neuro-psychopharmacology & biological psychiatry. 2002, Vol 26, Num 3, pp 609-611, issn 0278-5846Article
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline : Interventions, Part IIIYOUDIM, Moussa B. H; WEINSTOCK, Marta.Mechanisms of ageing and development. 2002, Vol 123, Num 8, pp 1081-1086, issn 0047-6374Conference Paper
The effects of trazodone on sleep disturbances induced by brofaromineHAFFMANS, P. M. J; VOS, M. S.European psychiatry. 1999, Vol 14, Num 3, pp 167-171, issn 0924-9338Article
Clinical pharmacology of befloxatone : a brief reviewROSENZWEIG, P; PATAT, A; CURET, O et al.Journal of affective disorders. 1998, Vol 51, Num 3, pp 305-312, issn 0165-0327Article
Pharmacotherapy of dysthymic and chronic depressive disorders : overview with focus on moclobemideVERSIANI, M.Journal of affective disorders. 1998, Vol 51, Num 3, pp 323-332, issn 0165-0327Article
Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase a inhibitors, pirlindole and moclobemide, in the treatment of depressionTANGHE, A; GEERTS, S; VAN DORPE, J et al.Acta psychiatrica Scandinavica. 1997, Vol 96, Num 2, pp 134-141, issn 0001-690XArticle
Moclobemide in social phobia : A controlled dose-response trialNOYES, R. JR; MOROZ, G; LYDIARD, R. B et al.Journal of clinical psychopharmacology. 1997, Vol 17, Num 4, pp 247-254, issn 0271-0749Article
Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor MoclobemideDINGEMANSE, J; GUENTERT, T; GIESCHKE, R et al.Journal of cardiovascular pharmacology. 1996, Vol 28, Num 6, pp 856-861, issn 0160-2446Article
Responders and non-responders to drug treatment in social phobia : differences at baseline and prediction of responseSLAAP, B. R; VAN VLIET, I. M; WESTENBERG, H. G. M et al.Journal of affective disorders. 1996, Vol 39, Num 1, pp 13-20, issn 0165-0327, 7 p.Article
Determination of fluoxetine hydrochloride in capsules and moclobemide in tablets by first, second and third derivative spectrophotometryMISZTAL, G; SKIBINSKI, R.Pharmazie. 1999, Vol 54, Num 7, pp 550-551, issn 0031-7144Article
Artificial neural networks : a study in clinical psychopharmacologyPOLITI, E; BALDUZZI, C; BUSSI, R et al.Psychiatry research. 1999, Vol 87, Num 2-3, pp 203-215, issn 0165-1781Article
Galactorrhoea with moclobemideDUNN, N. R; FREEMANTLE, S. N; PEARCE, G. L et al.Lancet (British edition). 1998, Vol 351, Num 9105, issn 0140-6736, p. 802Article
The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patientsPLENKER, A; PÜCHLER, K; VOLZ, H.-P et al.International clinical psychopharmacology. 1997, Vol 12, pp S25-S29, issn 0268-1315, SUP5Article
Quality-monitoring of psychotropic drug therapy in post-marketing surveillance : Results of a drug utilization observation (DUO) study on moclobemideLAUX, G; BAIER, D.Pharmacopsychiatry. Supplement. 1997, Vol 30, Num 1, pp 21-27, issn 0936-9589Article
What happens to patients after the end of a clinical trial ? Systematic follow-up observational study of an open moclobemide trial in major depressionLINDEN, M; BAIER, D; GOTHE, H et al.Pharmacopsychiatry. Supplement. 1997, Vol 30, Num 1, pp 35-43, issn 0936-9589Article